Tags

Type your tag names separated by a space and hit enter

New options for treatment of Parkinson's disease.
Baillieres Clin Neurol. 1997 Apr; 6(1):109-23.BC

Abstract

New medications recently developed for treating Parkinson's disease include two inhibitors of catechol-O-methyltransferase (COMT), entacapone and tolcapone, which, by decreasing the elimination of levodopa, extend the duration of its effects. Increased 'on' time and less 'wearing-off' symptomatology can be expected with the use of these COMT inhibitors. Two non-ergot dopaminergic agonists (pramipexole and ropinirole) and a long-acting ergoline (cabergoline) are also being introduced. These dopaminergic agonists, like the ergot derivatives currently available (bromocriptine, lisuride, and pergolide), are useful as adjuncts to levodopa, and are also efficacious as monotherapies.

Authors+Show Affiliations

LeWitt PA
Wayne State University School of Medicine, Detroit, Michigan, USA.

MeSH

Antiparkinson AgentsBenzophenonesBenzothiazolesCabergolineCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsCatecholsEnzyme InhibitorsErgolinesGuidelines as TopicHumansIndolesNitrilesNitrophenolsParkinson DiseasePramipexoleThiazolesTolcaponeTreatment Outcome

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9426871

Citation

LeWitt, P A.. "New Options for Treatment of Parkinson's Disease." Bailliere's Clinical Neurology, vol. 6, no. 1, 1997, pp. 109-23.
LeWitt PA. New options for treatment of Parkinson's disease. Baillieres Clin Neurol. 1997;6(1):109-23.
LeWitt, P. A. (1997). New options for treatment of Parkinson's disease. Bailliere's Clinical Neurology, 6(1), 109-23.
LeWitt PA. New Options for Treatment of Parkinson's Disease. Baillieres Clin Neurol. 1997;6(1):109-23. PubMed PMID: 9426871.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New options for treatment of Parkinson's disease. A1 - LeWitt,P A, PY - 1997/4/1/pubmed PY - 1998/1/14/medline PY - 1997/4/1/entrez SP - 109 EP - 23 JF - Bailliere's clinical neurology JO - Baillieres Clin Neurol VL - 6 IS - 1 N2 - New medications recently developed for treating Parkinson's disease include two inhibitors of catechol-O-methyltransferase (COMT), entacapone and tolcapone, which, by decreasing the elimination of levodopa, extend the duration of its effects. Increased 'on' time and less 'wearing-off' symptomatology can be expected with the use of these COMT inhibitors. Two non-ergot dopaminergic agonists (pramipexole and ropinirole) and a long-acting ergoline (cabergoline) are also being introduced. These dopaminergic agonists, like the ergot derivatives currently available (bromocriptine, lisuride, and pergolide), are useful as adjuncts to levodopa, and are also efficacious as monotherapies. SN - 0961-0421 UR - https://www.unboundmedicine.com/medline/citation/9426871/New_options_for_treatment_of_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -